Please login to the form below

Not currently logged in
Email:
Password:

PD-1

This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.

Pivotal data sets up Tecentriq filing in small cell lung cancer

Pivotal data sets up Tecentriq filing in small cell lung cancer

Roche’s PD-L1 inhibitor Tecentriq has become the first cancer immunotherapy to improve survival in extensive-stage small cell lung cancer (ES-SCLC), putting it on course to end a ... The company is currently running a phase III trial ( KeyNote-604) of

Latest news

More from news
Approximately 21 fully matching, plus 233 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms. ... used to progress the clinical development of the company's immuno-oncology

  • The good, the bad and the ugly The good, the bad and the ugly

    But that doesn’t tell the whole story. Pfizer comfortably remains the world’s largest pharma company (by global Rx sales), with an estimated 12.1% growth in 2017, lifting its ... Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Pharma deals continue to slide Pharma deals continue to slide

    1, 410 (upfront 80). WuXi Biologics and Gloria Pharma (CN). Arcus Biosciences (US). ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for treatment of cancer.

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.

  • Immuno-oncology: The market opportunity for PD-1/PD-L1s

    Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1

  • Immuno-oncology: The market opportunity for PD-1/PD-L1s

    Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1

  • Research Partnership

    Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director. ... Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics